Increasing Lung Disease in Systemic JIA
A single-center cohort analysis shows that lung disease (LD) is increasingly seen in children…
View Resource
First Line IL-1 Inhibition in Systemic JIA
First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective…
View Resource
Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic…
View Resource
Genetic Diagnosis for Previously Undiagnosed Disorders
The NEJM has reported the NIH’s Undiagnosed Diseases Network (UDN) study results of genetically…
View Resource
IL-6 for Adult Still's: A New Option?
Some clinical benefits were seen among patients with adult-onset Still’s disease treated with tocilizumab…
View Resource
Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in…
View Resource
Genetic Breakthrough in Systemic JIA
The identification of a genetic susceptibility locus for systemic juvenile idiopathic arthritis (sJIA) has…
View Resource
Kineret Approved for Still's Disease in EU
SOBI has announced that Kineret (anakinra) has been approved by the European Commission (EC)…
View Resource
IL-6 Inhibition Most Effective in Polycyclic Systemic JIA
The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6 inhibitor…
View Resource
IL-18 Binding Protein Effective in Adult-Onset Still's Disease
Gabay and colleagues have reported the results of a novel new recombinant human IL-18…
View Resource